A

s oncologists race forward with new treatments verging on science fiction and biotech companies press on with drugs for once-hopeless rare disorders, one of the world’s most pervasive diseases looks like it’s been left behind.

There are few new drugs on the horizon for diabetes, which affects about 29 million Americans. Most of the treatments in late-stage development are simply improved versions of what’s out there — taken weekly versus daily, or orally instead of by injection.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • My wife is diabetic for last 10yrs.for last 6 months she is under teniligleptin 20mg morning and glimipride 1mgln the evening. Her recent Fbs was 116mg/dl.so I need your comment for my future plans.

  • Beautifully return. Especially the concluding sentence. It would be nice if the author also writes a follow up new classes of emerging drugs and the difficulties involved like glucagon receptor antagonist, adiponectin agonist, immunomodulators etc.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X